FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 353:1300 September 22, 2005 Number 12 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Paik, S. PubMed Citation

To the Editor: The use of the Oncotype DX assay in the study reported by Paik et al. (Dec. 30 issue)¹ is an example of a conflict of interest. Most of the authors of the report are employed by, receive consulting fees from, or hold equity positions or stock options in Genomic Health, the manufacturer of Oncotype DX. These authors support the adoption of a $3,000 test in lieu of information already contained in a standard surgical pathology report — the tumor grade. Table 1 of their article shows risk categories as determined by the Oncotype DX assay and the . . . [Full Text of this Article]

This article has been cited by other articles:

• Linke, S. P., Bremer, T. M., Herold, C. D., Sauter, G., Diamond, C. (2006). A Multimarker Model to Predict Outcome in Tamoxifen-Treated Breast Cancer Patients. Clin. Cancer Res. 12: 1175-1183 [Abstract] [Full Text]